March 22, 2019 6:35pm

… 40 of 45 covered companies didn’t pay-off with the IBB closing down -3.39%

Volume was low as 1 out of the 2 upside had higher (than the 3 month average) volume and 17 out of the 40 downside experienced greater volume (than the 3 month average)

… Algorithms, algorithms compute me your “rules”

Q4 and FY18 financial results: Neuralstem (CUR)

Pre-open indications: 7 HIT and 1 MISS

 

Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.


That’s why my “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

 

Markets and indexes:

  • The Dow closed down -460.19 points or -1.17% to 25,502.32
  • The S&P closed down -54.17 points or -1.90% to 2,800.71
  • The NASDAQ was down -196.29 points or -2.50% to 7,642.67

 

Henry’omics:

Sector equities plummeted on Friday as risk to clinical stage companies was highlighted by Biogen’s (BIIB) gigantic depreciation, fears of others in the biotech field, the Fed’s cautious economic forecast igniting investor anxiety going into the weekend.

... Of MY covered composite of 45 companies, 33 have reported and there are a few next week.

Friday also saw more weak economic data from around the world that stoked those fears.

  • IHS Markit said manufacturing activity in Germany dropped to its lowest level in more than six years in March. In France, manufacturing and services slowed down to their lowest levels in three months and two months, respectively. For the euro zone as a whole, manufacturing fell to its lowest level since April 2013. These data sent the German 10-year bund yield briefly into negative territory, its lowest level since 2016.

Despite the decline on Friday, the DOW was up +9.2% for the year. The S&P 500 is up +11.7% and NASDAQ is up 15.2%.

 

Sector equities posted Thursday’s gains were only 2: MDXG (+$0.11) and BCLI (+$0.07)

  • Thursday’s review: SAGE (+$5.52 after Wednesday’s -$3.64), BLUE (+$2.60 after Wednesday’s -$2.52), QURE (+$2.59), ALNY (+$2.06) and RGNX (+$1.86 after Wednesday’s +$2.01, Tuesday’s +$0.22 and Monday’s +$0.84)

Crashing on Thursday was:  BLUE (-$9.54), ALNY (-$6.22), QURE (-$4.98), RGNX (-$4.66) and RARE (-$4.39)

  • Thursday’s review: RENE.L (-$1.00 after Wednesday’s +$1.50 Tuesday’s -$1.00 and Monday’s +$6.00) CLLS (-$0.41), BLCM (-$0.40 after Wednesday’s +$0.34), ONCE (-$0.23) and SLDB (-$0.13)

 

Pre-open post, “gain or pain, a Friday, mid-month of March’s 15 sessions, having 5 negative and 10 positive closes in the market casino, after a week of split decisions; the dice are cold?”

 

The advance/decline line scenario of 45 covered companies:  

  • The open was negative with the A/DL to 10/31, 3 flat3 and 1 acquired (AST);
  • The mid-day was negative with an A/DL of 3/39 and 2 flats and 1 acquired;
  • The close was negative with an A/DL of 2/40 and 2 flats and 1 acquired;

 

Q4 and FY18 financial results: Neuralstem (CUR)

  • NO quarterly reporting …

Net loss for FY18 was $4.9 M, or $0.32 per share (basic), compared to a loss of $15.7 M, or $1.20 per share (basic), for FY17. 

Cash position was $5.8 M and a runway lasting until Q3/19

 

Pre-open indications: 7 HIT and 1 MISS

  • Vericel (VCEL) closed down -$1.15 – hit;
  • uniQure NV (QURE) closed down -$4.98 – hit;
  • Regenxbio (RGNX) closed down -$4.66 – hit;
  • Sage Therapeutics (SAGE) closed down -$1.26 – miss;
  • CRISPRS Therapeutics (CRSP) closed down -$2.27 – hit;
  • Editas Medicine (EDIT) closing down -$2.13 – hit;
  • Intellia Therapeutics (NTLA) closing down -$1.46 – hit;
  • ReNeuron (RENE.L) closed flat at $75.00 with 30.5 K shares traded – hit;

 

Tonight’s percentage (%) indicators: 

  • Range of the 2 upside was +1.73% (BCLI) to +3.33% (MDXG) while the 40 downside ranged from -0.24% (ONCE) to -9.29% (SGMO).

Volume stat: 

  • 1 out of the 2 upside had higher (than the 3 month average) volume
  • 17 out of the 40 downside experienced greater volume (than the 3 month average)

2 flat - KOOL and RENE.L with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Friday was down -3.39%;
  • Thursday was down -1.07%;
  • Wednesday was down -0.59%;
  • Tuesday was down -0.06%;
  • Monday was down -0.31% after NOT indicating;
  • Last Friday was up +1.07% after indicating a positive +0.26% in the pre-market;

 

March sessions:

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.